All In Biotech

NDA 020793 · Hikma

Cafcit

Caffeine Citrate · Intravenous, Oral

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 2, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Sep 21, 1999

Approved uses

2

Original approval plus efficacy supplements

Registered trials

411

59 Phase 3, 38 recruiting

FAERS reports

2,330

2,271 serious, 1,231 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 8, 2024.

INDICATIONS AND USAGE Caffeine Citrate Injection is indicated for the treatment of apnea of prematurity.

Mechanism: Mechanism of Action Caffeine is structurally related to other methylxanthines, theophylline, and theobromine. It is a bronchial smooth muscle relaxant, a CNS stimulant, a cardiac muscle stimulant, and a diuretic. Although the mechanism of action of caffeine in apnea of prematurity is not known, several mechanisms have been hypothesized. These include: (1) stimulation of the respiratory center, (2) increased minute ventilation, (3) decreased threshold to hypercapnia, (4) increased response to hypercapnia, (5) increased skeletal muscle tone, (6) decreased diaphragmatic fatigue, (7) increased...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 12, 2000 Supplement 1 · Efficacy LetterLabel
  • Sep 21, 1999 Original approval · Type 2 - New Active Ingredient · priority review ReviewLetterLabel
2 products under this application
  • CAFCIT · CAFFEINE CITRATE EQ 30MG BASE/3ML (EQ 10MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • CAFCIT · CAFFEINE CITRATE EQ 30MG BASE/3ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Caffeine" as an intervention, any sponsor and status, largest first.

All 411 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pemphigus1,007
  • hepatic enzyme increased974
  • glossodynia972
  • pericarditis960
  • alopecia954
  • hand deformity950
  • joint swelling944
  • anti-cyclic citrullinated peptide antibody positive931
  • rheumatoid arthritis931
  • arthropathy925
  • discomfort925
  • pain924

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20058
200720
200861
200919
201034
201145
201247
201311
20148
20159
201610
201719
2018113
201967
2020108
2021234
2022265
2023268
2024407
2025374
2026202

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,521 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.